Body fluid micro(mi)RNAs as biomarkers for human cancer

Journal of Nucleic Acids Investigation

Volumn 2, Issue 1, 2011, Pages 1-4

  Patel, Neel ^a   Sauter, Edward R ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Biomarkers; Cancer; miRNAs

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 10B; MICRORNA 125A; MICRORNA 126; MICRORNA 141; MICRORNA 152; MICRORNA 155; MICRORNA 17 3P; MICRORNA 182; MICRORNA 195; MICRORNA 199A; MICRORNA 200A; MICRORNA 200B; MICRORNA 21; MICRORNA 210; MICRORNA 223; MICRORNA 24; MICRORNA 25; MICRORNA 26A; MICRORNA 29A; MICRORNA 30D; MICRORNA 31; MICRORNA 375; MICRORNA 638; MICRORNA 92; MICRORNA 92A; UNCLASSIFIED DRUG;

ARTICLE; BODY FLUID; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; CANCER RISK; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; NON INVASIVE PROCEDURE; NONHUMAN; PLEURA EFFUSION; PROGNOSIS; SALIVA LEVEL; URINE LEVEL;

EID: 80052190967     PISSN: None     EISSN: 20356005     Source Type: Journal    
DOI: 10.4081/jnai.2011.e1     Document Type: Article

References (40)

1. Heneghan HM, Miller N, Lowery AJ, et al. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009;2009:950201.
2. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res 2008;10:203.
3. Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009;62:771-6.
4. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clinical chemistry. 2009;55:623-31.
5. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008;14:360-5.
6. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005;435:745-6.
7. White NM, Yousef GM. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med 2010;8:65.
8. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
9. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010;9: 306-14.
10. Valenti R, Huber V, Iero M, et al. Tumorreleased microvesicles as vehicles of immunosuppression. Cancer Res 2007;67: 2912-15.
11. Du L, Pertsemlidis A. microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev 2010;29:109-22.
12. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol 2010;4:230-41.
13. Manne U, Shanmugam C, Katkoori VR, Bumpers HL. miRNAs as biomarkers for management of patients with colorectal cancer. Biomarkers in Med 2010;4:761-70.
14. Wang J, Wang Q, Liu H, et al. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer letters 2010;297: 137-43.
15. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer research 2008;68:8535-40.
16. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353: 1793-801.
17. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nature reviews 2005;5:845-56.
18. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
19. Chen YT, Kitabayashi N, Zhou XK, et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008;21:1139-46.
20. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular cancer 2006;5:24.
21. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clinical chemistry 2010;56:1733-41.
22. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 2010;3: 109-13.
23. Mithcell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008;105:10513-8.
24. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
25. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
26. Asaga S, Kuo C, Nguyen T, et al. Direct Serum Assay for microRNA-21 Concentra -tions in Early and Advanced Breast Cancer. Clin Chem 2011;57:84-91.
27. Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010;15:673-82.
28. Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer 2010;17:F91-104.
29. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
30. Liu CJ, Kao SY, Tu HF, et al. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010;16:360-4.
31. Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010;60:351-7.
32. Zhang C, Wang C, Chen X, et al. Expression Profile of MicroRNAs in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma. Clin Chem 2010;56:1871-9.
33. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21.
34. Xie L, Chen X, Wang L, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010;10:591.
35. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010;28:655-61.
36. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-7.
37. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.
38. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-331.
39. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251:499-505.
40. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009; 2:89.